Central Nervous System-related Graft-versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Intern Med. 2021;60(20):3299-3304. doi: 10.2169/internalmedicine.6351-20. Epub 2021 Oct 15.

Abstract

Allogeneic hemopoietic stem cell transplantation (allo-HSCT) is the only curative therapy for refractory hematological malignancies. However, there are many treatment-related complications, including organ disorders, graft-versus-host disease (GVHD), and infectious diseases. Furthermore, there are many unclear points regarding central nervous system (CNS) complications, and the prognosis in patients with CNS complications is extremely poor. We herein report a 49-year-old woman who developed CNS-GVHD after a second transplantation for therapy-related myelodysplastic syndrome. CNS-GVHD in this case was refractory to all treatments, including steroids, and progressed. We also present a review of the literature about the symptoms, diagnosis, and treatment of CNS-GVHD.

Keywords: allogeneic hematopoietic stem cell transplantation; central nervous system complications; central nervous system graft-versus-host disease; graft-versus-host disease.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Central Nervous System
  • Female
  • Graft vs Host Disease* / diagnosis
  • Graft vs Host Disease* / etiology
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Middle Aged
  • Myelodysplastic Syndromes* / therapy